Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 1;8(4):002425.
doi: 10.12890/2021_002425. eCollection 2021.

Prostate Cancer and Reactive Haemophagocytic Lymphohistiocytosis

Laura Dumont  1 , Adriano Salaroli  2 , Lissandra Dal Lago  1 , Thierry Gil  1 , Thierry Pepersack  1
Affiliations

Prostate Cancer and Reactive Haemophagocytic Lymphohistiocytosis

Laura Dumont et al. Eur J Case Rep Intern Med. .

Abstract

We report the case of a 76-year-old man presenting with reactive haemophagocytic lymphohistiocytosis (rHLH) in the setting of disseminated prostate cancer. This often fatal syndrome must be diagnosed early in order to maximize survival. Treatment should be initiated whenever the clinical diagnosis is suspected, even if the HLH-2004 criteria are not met. The HScore is a useful diagnostic tool for rHLH. In case of neurological symptoms, an extensive assessment must be performed. The goal of this case report is to raise awareness of this rare syndrome among oncologists.

Learning points: The association of prostate cancer and reactive haemophagocytic lymphohistiocytosis (rHLH) has rarely been described.This often fatal syndrome must be recognized early in order to start specific treatment and maximize survival.Specific treatment for rHLH must be accompanied by treatment of the triggering factors.

Keywords: HScore; Prostate cancer; hyperferritinemia; hypertriglyceridemia; pancytopenia; reactive hemophagocytic lymphohistiocytosis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interests: The Authors declare that there are no competing interests.

References

    1. Koizumi K, Haseyama Y, Machino R, Sato Y, Sawada K, Koike T. The hemophagocytic syndrome in prostate cancer revealed by disseminated carcinomatosis of the bone marrow. J Urol. 2002;168(3):1101–1102. - PubMed
    1. Declerck L, Adenis C, Amela E, Caty A, Adenis A, Penel N. Prostate cancer related haemophagocytic syndrome: successful treatment with chemotherapy. Acta Oncol. 2012;51(2):268–269. - PubMed
    1. Bergsten E, Horne A, Aricó M, Astigarraga I, Egeler RM, Filipovich AH, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728–2738. - PMC - PubMed
    1. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome: score for reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–2620. - PubMed
    1. Vaidya HC, Wolf BA, Garrett N, Catalona WJ, Clayman RV, Nahm MH. Extremely high values of prostate-specific antigen in patients with adenocarcinoma of the prostate; demonstration of the ‘hook effect’. Clin Chem. 1988;34(10):2175–2177. - PubMed

LinkOut - more resources